咪唑斯汀抗组胺点刺试验及治疗荨麻疹临床疗效观察

Prick test and clinical efficacy of mizolastine in the treatment of urticaria

目的:评价咪唑斯汀治疗荨麻疹的疗效及安全性。方法:①对93例急、慢性荨麻疹患者口服咪唑斯汀10mg,每日1次,急性荨麻疹患者首次服药后留观2h,慢性荨麻疹患者连续用药2周。②选择10名健康志愿者作组胺点刺试验,观察咪唑斯汀对组胺诱导风团的抑制作用。结果:①61例急性荨麻疹患者首次服药后在1h内起效49例(80.3%);32例慢性荨麻疹治疗1周后有效率为90.6%,治疗2周后有效率为100.0%。3例患者出现短暂而轻度的嗜睡反应。②健康志愿者服用咪唑斯汀1、2h后,对组胺诱导风团的抑制率分别为40.19%和83.92%;红晕抑制率分别为49.90%和87.69%。结论:咪唑斯汀治疗急、慢性荨麻疹起效快,作用持久,不良反应少。

Objective: To evaluate the efficacy and safety of mizolastine in the treatment of urticaria. Methods: ①Ninety-three acute and chronic urticaria patients were treated with mizolastine 10 mg once a day. The acute urticaria patients were observed for 2 h after mizolastine was taken for the first time and the chronic ones were taken the medicine daily for 14 days. ②10 healthy volunteers were chosen for histamine prick test and observed the inhibitory action of mizolastine on the histamine induced wheal. Results: ①80.3% of the acute urticaria patients markedly improved in one hour after taking the medicine for the first time; after 7 days and 14 days, the total effective rates of 32 patients with chronic urticaria were 90.6% and 100%,respectively. A transient and mild drowsiness side effect was observed in 3 patients. ② In the healthy volunteers, the inhibitory rates of histamine induced wheal were 40.19% and 83.92% respectively, the inhibitory rates of flush were 49.90% and 87.69% respectively 1 h and 2 h after taking mizolastine. Conclusion: Mizolastine is an effective and safe drug in the treatment of acute and chronic urticaria.